Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How safe is isoniazid?

J E Thompson

    The Medical Journal of Australia
    |February 11, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Isoniazid (INH) chemoprophylaxis offers significant benefits outweighing hepatitis risks, especially for those under 50. Central nervous system disorders and hypersensitivity were also noted complications.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Black Hole Spectroscopy and Tests of General Relativity with GW250114.

    Physical review letters·2026
    Same author

    GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

    Physical review letters·2025
    Same author

    Camphor an Antidote to Strychnia-Experiment-Failure, &c. &c.

    Medical examiner (Philadelphia, Pa.)·2023
    Same author

    Regional long-term analysis of dietary isotopes in Neolithic southeastern Italy: new patterns and research directions.

    Scientific reports·2023
    Same author

    Foreign Correspondence: Letter from Prof. J. E. Thompson, M. D.

    Daniel's Texas medical journal·2023
    Same author

    Operative Procedures in Glandular Tumors of the Neck.

    Texas medical journal (Austin, Tex.)·2023
    Same journal

    Responding to the Revised First Nations Health and Cultural Safety Accreditation Standards in Australian Primary Medical Education: Institutional Principles and Qualities for Meaningful Progress.

    The Medical journal of Australia·2026
    Same journal

    Multimorbidity Clusters Among People Aged 65 Years and Over in Australia: A Nationwide Cross-Sectional Data Linkage Study.

    The Medical journal of Australia·2026
    Same journal

    Reducing Nitrous Oxide Emissions Across the Melbourne Biomedical Precinct.

    The Medical journal of Australia·2026
    Same journal

    Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population.

    The Medical journal of Australia·2026
    Same journal

    Striving for Racial Equity in Oral Cancer Research: A Case Study.

    The Medical journal of Australia·2026
    Same journal

    Progressing Cross-Sector Collaboration for People With Eating Disorders and Higher Weight: Priority Actions From an Expert Roundtable Using a Modified Nominal Group Technique.

    The Medical journal of Australia·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Hepatology

    Background:

    • Investigated complications of isoniazid (INH) in 1033 patients receiving treatment for at least 18 months.
    • Assessed adverse events associated with INH, alone or in combination with other drugs.

    Observation:

    • Hepatitis occurred in 25 patients, with varied attributions including rifampicin, infectious hepatitis, INH, and co-treatment.
    • Central nervous system disorders, primarily peripheral neuropathy, affected 12 patients over 40 years old.
    • Hypersensitivity to INH was observed in 12 patients.

    Findings:

    • Distinguishing INH-induced hepatitis from rifampicin-induced hepatitis presented challenges.
    • The benefits of INH chemoprophylaxis were found to outweigh the risks of hepatitis.

    Related Experiment Videos

  • Risk-benefit analysis favored INH use, particularly in patients younger than 50 years.

    • Implications:

    • Highlights the importance of monitoring for hepatitis and neurological adverse events during INH therapy.
    • Supports the continued use of INH chemoprophylaxis, with careful consideration of patient age and risk factors.
    • Informs clinical decision-making regarding tuberculosis prevention strategies.